Public-Private Partnership CEPI operates as a broad alliance spanning public, private, philanthropic and civil organizations, presenting opportunities to position enterprise solutions that support multi-stakeholder collaboration, governance, and secure data sharing across partners.

100 Days Mission The drive to develop vaccines within 100 days signals a need for rapid de-risking, fast-track project management, scalable clinical trial support, agile supply chain solutions, and streamlined regulatory analytics tools to accelerate timelines.

Funding Momentum With recent $50 million funding influx from the U.S. Department of State and ongoing pursuit of billions for CEPI 3.0, there are opportunities to offer grant management platforms, financial forecasting, compliance tooling, and programmatic reporting tailored to large, mission-critical initiatives.

Collaborative R&D Active partnerships with Moderna, DIOSynVax, SK Bioscience, Pop Biotechnologies and others indicate a strong market for collaboration platforms, IP management, data integration, and secure collaboration environments that support joint vaccine development programs.

Vaccine Platform Expansion CEPI funds and advances multiple platform technologies (mRNA, nanoparticle vaccines, and novel antigens), creating sales opportunities for end-to-end R&D tooling, manufacturing process analytics, LIMS/ELN systems, and digital quality management tailored to biotech experimentation and scale-up.